Stock Overview

Medirom Healthcare Technologies Inc (MRM)

NASDAQ · Consumer Cyclical · Personal Services

Medirom Healthcare Technologies Inc is a Consumer Cyclical company with a market capitalization of $7.88M and a trailing P/E ratio of 2.7.

Market Cap
$7.88M
P/E (TTM)
2.7
Price/Sales
0.0
Price/Book
5.1
EV/EBITDA
14.9
Beta
1.00
EPS (TTM)
$0.37
Profit Margin
0.5%
ROE
53.2%
52W High
$3.53
52W Low
$0.90

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025 · in JPY

Revenue
4.04M JPY
Gross Profit
3.90M JPY
Operating Income
414.31K JPY
Net Income
374.72K JPY
Free Cash Flow
-1.90B JPY
Total Debt
1.74B JPY
Cash & Equivalents
20.14M JPY
Shareholder Equity
1.33B JPY

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q3 2025October 21, 2025$-87.38$0.00
Q1 2025April 29, 2025$110.27$0.00
Q3 2024November 7, 2024$-118.56$0.00
Q1 2021May 17, 2021$-0.48$0.00
Q4 2020March 31, 2021$-0.48$0.00
Q3 2020December 31, 2020$-0.12$0.00

Other Personal Services Stocks

Frequently Asked Questions

What is Medirom Healthcare Technologies Inc's market cap?

As of June 29, 2026, Medirom Healthcare Technologies Inc (MRM) has a market capitalization of $7.88M.

What is Medirom Healthcare Technologies Inc's P/E ratio?

Medirom Healthcare Technologies Inc trades at a trailing price-to-earnings (P/E) ratio of 2.7.

Does Medirom Healthcare Technologies Inc pay a dividend?

Medirom Healthcare Technologies Inc does not currently pay a dividend.

What sector is MRM in?

Medirom Healthcare Technologies Inc is in the Consumer Cyclical sector, specifically the Personal Services industry.

What was Medirom Healthcare Technologies Inc's revenue?

In its latest reported fiscal year (ending December 31, 2025), Medirom Healthcare Technologies Inc reported revenue of 4.04M JPY and net income of 374.72K JPY.

Ask your own questions about MRM

Try mrmarket.ai free

Data as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.